Performance of plasminogen activator inhibitor-1 as a biomarker in patients undergoing coronary angiography: Analytical and biological considerations

Jung, Richard G.; Simard, Trevor; Santo, Pietro Di; Labinaz, Alisha; Moreland, Robert B.; Duchez, Anne‐Claire; Majeed, Kamran; Motazedian, Pouya; Rochman, Rebecca; Jung, Young; Hibbert, Benjamin

doi:10.1177/1479164119845123

Cited by 13 publications

(11 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Coronary angiography is the golden standard for the diagnosis of CVD. Left main artery (LM), left anterior descending artery (LAD), cyclotron artery (LCX) and right coronary artery (RCA) with stenosis over 50% defined CVD [9]. For coronary angiography, we used GE digital plate angiography system (INNOVA 4100 IQ).…”

Section: Definition Of Cvdmentioning

confidence: 99%

Associations of multiple serum biomarkers and the risk of cardiovascular disease in China

Yao¹,

Hou

Liu

et al. 2020

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background Previous studies focus on one or several serum biomarkers and the risk of cardiovascular disease (CVD). This study aims to investigate the association of multiple serum biomarkers and the risk of CVD and evaluate the dose-relationship between a single serum metabolite and CVD. Methods Our case-control study included 161 CVD and 160 non-CVD patients who had a physical examination in the same hospital. We used stratified analysis and cubic restricted analysis to investigate the dose-response relationship of individual serum biomarkers and the CVD incident. Moreover, to investigate serum biomarkers and CVD, we used elastic net regression and logistic regression to build a multi-biomarker model. Results In a single serum biomarker model, we found serum FT4, T4. GLU, CREA, TG and LDL-c were positively associated with CVD. In the male group, serum T4, GLU and LDL-c were positively associated with CVD; and serum TG was positively associated with CVD in the female group. When patients ≤63 years old, serum T4, GLU, CREA and TG were positively associated with CVD, and serum TG and LDL-c were positively associated with CVD when patients > 63 years old. Moreover, serum GLU had nonlinearity relationship with CVD and serum TG and LDL-c had linearity association with CVD. Furthermore, we used elastic regression selecting 5 serum biomarkers (GLU, FT4, TG, HDL-c, LDL-c) which were independently associated with CVD incident and built multi-biomarker model. And the multi-biomarker model had much better sensitivity than single biomarker model. Conclusion The multi-biomarker model had much higher sensitivity than a single biomarker model for the prediction of CVD. Serum FT4, TG and LDL-c were positively associated with the risk of CVD in single and multiple serum biomarkers models, and serum TG and LDL-c had linearity relationship with CVD.

show abstract

Section: Definition Of Cvdmentioning

confidence: 99%

Associations of multiple serum biomarkers and the risk of cardiovascular disease in China

Yao¹,

Hou

Liu

et al. 2020

BMC Cardiovasc Disord

View full text Add to dashboard Cite

show abstract

“…Another important factorial assay of the fibrinolysis pathway is PAI-1. The performance of PAI-1 as a biomarker has been reported to be comparable to established clinicallyutilised biomarkers such as NT-proBNP and C-reactive protein [20]. Nonetheless, PAI-1 may be affected by various external factors.…”

Section: Plasminogen Activator Inhibitor-1mentioning

confidence: 94%

Assessment of endogenous fibrinolysis in clinical practice using novel tests: ready for clinical roll-out?

et al. 2021

View full text Add to dashboard Cite

The occurrence of thrombotic complications, which can result in excess mortality and morbidity, represent an imbalance between the pro-thrombotic and fibrinolytic equilibrium. The mainstay treatment of these complications involves the use of antithrombotic agents but despite advances in pharmacotherapy, there remains a significant proportion of patients who continue to remain at risk. Endogenous fibrinolysis is a physiological counter-measure against lasting thrombosis and may be measured using several techniques to identify higher risk patients who may benefit from more aggressive pharmacotherapy. However, the assessment of the fibrinolytic system is not yet accepted into routine clinical practice. In this review, we will revisit the different methods of assessing endogenous fibrinolysis (factorial assays, turbidimetric lysis assays, viscoelastic and the global thrombosis tests), including the strengths, limitations, correlation to clinical outcomes of each method and how we might integrate the assessment of endogenous fibrinolysis into clinical practice in the future.

show abstract

“…This study conforms to the 1975 Declaration of Helsinki for the use of human blood. The University of Ottawa Heart Institute serves 1.2 million people with all cardiac catheterization procedures prospectively indexed in the Cardiovascular and Percutaneous Clinical Trials (CAPITAL) revascularization registry along with baseline investigations and medications 42,43 . From August 2018 to March 2019, blood samples were collected from 21 patients in EDTA tubes (Becton Dickinson, Franklin Lakes, New Jersey) at the time of coronary angiography.…”

Section: Methodsmentioning

confidence: 99%

The secretome of liver X receptor agonist-treated early outgrowth cells decreases atherosclerosis in Ldlr−/− mice

Rasheed

Shawky

Tsai

et al. 2020

Stem Cells Translational Medicine

Self Cite

View full text Add to dashboard Cite

Endothelial progenitor cells (EPCs) promote the maintenance of the endothelium by secreting vasoreparative factors. A population of EPCs known as early outgrowth cells (EOCs) is being investigated as novel cell-based therapies for the treatment of cardiovascular disease. We previously demonstrated that the absence of liver X receptors (LXRs) is detrimental to the formation and function of EOCs under hypercholesterolemic conditions. Here, we investigate whether LXR activation in EOCs is beneficial for the treatment of atherosclerosis. EOCs were differentiated from the bone marrow of wild-type (WT) and LXR-knockout (Lxrαβ−/−) mice in the presence of vehicle or LXR agonist (GW3965). WT EOCs treated with GW3965 throughout differentiation showed reduced mRNA expression of endothelial lineage markers (Cd144, Vegfr2) compared with WT vehicle and Lxrαβ−/− EOCs. GW3965-treated EOCs produced secreted factors that reduced monocyte adhesion to activated endothelial cells in culture. When injected into atherosclerosis-prone Ldlr−/− mice, GW3965-treated EOCs, or their corresponding conditioned media (CM) were both able to reduce aortic sinus plaque burden compared with controls. Furthermore, when human EOCs (obtained from patients with established CAD) were treated with GW3965 and the CM applied to endothelial cells, monocyte adhesion was decreased, indicating that our results in mice could be translated to patients. Ex vivo LXR agonist treatment of EOCs therefore produces a secretome that decreases early atherosclerosis in Ldlr−/− mice, and additionally, CM from human EOCs significantly inhibits monocyte to endothelial adhesion. Thus, active factor(s) within the GW3965-treated EOC secretome may have the potential to be useful for the treatment of atherosclerosis.

show abstract

Performance of plasminogen activator inhibitor-1 as a biomarker in patients undergoing coronary angiography: Analytical and biological considerations

Cited by 13 publications

References 17 publications

Associations of multiple serum biomarkers and the risk of cardiovascular disease in China

Associations of multiple serum biomarkers and the risk of cardiovascular disease in China

Assessment of endogenous fibrinolysis in clinical practice using novel tests: ready for clinical roll-out?

The secretome of liver X receptor agonist-treated early outgrowth cells decreases atherosclerosis in Ldlr−/− mice

Contact Info

Product

Resources

About